Evidence map›Paper›PMID 41273551›Full record

ArticleAdvances in experimental medicine and biology2026

Exploring Therapeutic and Multitarget Mechanism of Molsidomine on Cerebral Ischemia: Molecular Docking and Multifaceted In Silico Study.

Sohini Chakraborty, Akash Bhati, Krishna Sanka, Vijay Chidrawar, Raghavendra Mitta, Vinyas Mayasa, Raghavendra Babu Nayaka, Padmavathi Yenumula, Satarupa Banerjee, Vimal Arora and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sohini ChakrabortyDepartment of Biotechnology, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamilnadu, India.
Akash BhatiUniversity Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India.
Krishna SankaDepartment of Pharmaceutics, School of Pharmacy and Technology Management (SPTM), SVKM's Narsee Monjee Institute of Management Studies (NMIMS), Deemed to be University, Shirpur, Maharashtra, India.
Vijay ChidrawarSchool of Pharmacy and Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS), Deemed-to-university, Green Industrial Park, TSIIC, Jadcherla, Hyderabad, Telangana, India.
Raghavendra MittaDepartment of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology & Research (Deemed to be University), Vadlamudi, Guntur, Andhra Pradesh, India.
Vinyas MayasaDepartment of Pharmacology, GITAM School of Pharmacy, GITAM Deemed to be University, Hyderabad, Telangana, India.
Raghavendra Babu NayakaDepartment of Pharmaceutical Analysis, G.Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad, Telangana, India.
Padmavathi YenumulaDepartment of Pharmaceutical Analysis, G.Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad, Telangana, India.
Satarupa BanerjeeDepartment of Biotechnology, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamilnadu, India.
Vimal AroraUniversity Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India.
Hemanth Kumar BoyinaUniversity Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The innate immune response is started immediately following brain ischemia, resulting in adaptive immunity. More and more experimental evidence has indicated that the immune response caused by cerebral ischemia plays a crucial role during the initial brain damage and subsequent brain injury recovery. Molsidomine, a nitric oxide donor, has been found to reduce schizophrenia-like behavioral abnormalities in rats due to glutamate hypofunction. The current study sought to explore the efficacy of molsidomine versus conventional drugs in cerebral ischemia. This study scavenges literature to retrieve various genes like PI3K, MMP9, COX2, LOX, TLR4, AKT1, mTOR, NLRP3, STAT3, IL1β, NFκB, TNF, IL6, and TP53 involved in cerebral ischemia. A two-step molecular docking revealed significant gene-drug complexes followed by a protein-protein interaction (PPI). Additionally, oncoprint analysis, protein-protein interaction, and functional and pathway enrichment associated with these genes and a circos plot depicting the mutational profile of the genes are incorporated in this study. This comprehensive in-silico approach reveals the efficacy of the potency of the candidate drug, molsidomine in treating cerebral ischemia.

Indexed as

Brain IschemiaMolecular Docking SimulationNeuroprotective AgentsAnimalsComputer SimulationHumansProtein Interaction MapsSignal TransductionNeuroprotective AgentsCerebral ischemiaGene ontologyMolecular dockingMolsidomineSTRING

Identifiers

PMID41273551

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.